• Something wrong with this record ?

Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases

ML. Thomas, G. Shaddick, R. Charlton, C. Cavill, R. Holland, F. Iannone, G. Lapadula, S. Lopriore, J. Závada, M. Uher, K. Pavelka, L. Szczuková, P. Sidiropoulos, I. Flouri, A. Drosos, B. Möller, MJ. Nissen, RB. Müller, A. Scherer, N. McHugh, A....

. 2021 ; 48 (1) : 48-57. [pub] 20200401

Language English Country Canada

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026273

OBJECTIVE: To investigate whether tumor necrosis factor inhibitor (TNFi) combination therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARD) is more effective for psoriatic arthritis (PsA) and/or improves TNFi drug survival compared to TNFi monotherapy. METHODS: Five PsA biologics cohorts were investigated between 2000 and 2015: the ATTRA registry (Czech Republic); the Swiss Clinical Quality Management PsA registry; the Hellenic Registry of Biologics Therapies (Greece); the University of Bari PsA biologics database (Italy); and the Bath PsA cohort (UK). Drug persistence was analyzed using Kaplan-Meier and equality of survival using log-rank tests. Comparative effectiveness was investigated using logistic regression with propensity scores. Separate analyses were performed on (1) the combined Italian/Swiss cohorts for change in rate of Disease Activity Score in 28 joints (DAS28); and (2) the combined Italian, Swiss, and Bath cohorts for change in rate of Health Assessment Questionnaire (HAQ). RESULTS: In total, 2294 patients were eligible for the drug survival analysis. In the Swiss (P = 0.002), Greek (P = 0.021), and Bath (P = 0.014) databases, patients starting TNFi in combination with methotrexate had longer drug survival compared to monotherapy, while in Italy the monotherapy group persisted longer (P = 0.030). In eligible patients from the combined Italian/Swiss dataset (n = 1056), there was no significant difference between treatment arms in rate of change of DAS28. Similarly, when also including the Bath cohort (n = 1205), there was no significant difference in rate of change of HAQ. CONCLUSION: Combination therapy of a TNFi with a csDMARD does not appear to affect improvement of disease activity or HAQ versus TNFi monotherapy, but it may improve TNFi drug survival.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026273
003      
CZ-PrNML
005      
20220117123750.0
007      
ta
008      
211013s2021 xxc f 000 0|eng||
009      
AR
024    7_
$a 10.3899/jrheum.190815 $2 doi
035    __
$a (PubMed)32238520
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxc
100    1_
$a Thomas, Matthew L $u M.L. Thomas, PhD, Department of Mathematical Science, University of Bath, Bath, UK
245    10
$a Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases / $c ML. Thomas, G. Shaddick, R. Charlton, C. Cavill, R. Holland, F. Iannone, G. Lapadula, S. Lopriore, J. Závada, M. Uher, K. Pavelka, L. Szczuková, P. Sidiropoulos, I. Flouri, A. Drosos, B. Möller, MJ. Nissen, RB. Müller, A. Scherer, N. McHugh, A. Nightingale
520    9_
$a OBJECTIVE: To investigate whether tumor necrosis factor inhibitor (TNFi) combination therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARD) is more effective for psoriatic arthritis (PsA) and/or improves TNFi drug survival compared to TNFi monotherapy. METHODS: Five PsA biologics cohorts were investigated between 2000 and 2015: the ATTRA registry (Czech Republic); the Swiss Clinical Quality Management PsA registry; the Hellenic Registry of Biologics Therapies (Greece); the University of Bari PsA biologics database (Italy); and the Bath PsA cohort (UK). Drug persistence was analyzed using Kaplan-Meier and equality of survival using log-rank tests. Comparative effectiveness was investigated using logistic regression with propensity scores. Separate analyses were performed on (1) the combined Italian/Swiss cohorts for change in rate of Disease Activity Score in 28 joints (DAS28); and (2) the combined Italian, Swiss, and Bath cohorts for change in rate of Health Assessment Questionnaire (HAQ). RESULTS: In total, 2294 patients were eligible for the drug survival analysis. In the Swiss (P = 0.002), Greek (P = 0.021), and Bath (P = 0.014) databases, patients starting TNFi in combination with methotrexate had longer drug survival compared to monotherapy, while in Italy the monotherapy group persisted longer (P = 0.030). In eligible patients from the combined Italian/Swiss dataset (n = 1056), there was no significant difference between treatment arms in rate of change of DAS28. Similarly, when also including the Bath cohort (n = 1205), there was no significant difference in rate of change of HAQ. CONCLUSION: Combination therapy of a TNFi with a csDMARD does not appear to affect improvement of disease activity or HAQ versus TNFi monotherapy, but it may improve TNFi drug survival.
650    12
$a antirevmatika $x terapeutické užití $7 D018501
650    12
$a psoriatická artritida $x farmakoterapie $7 D015535
650    12
$a biologické přípravky $x terapeutické užití $7 D001688
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a lidé $7 D006801
650    _2
$a výsledek terapie $7 D016896
650    _2
$a inhibitory TNF $7 D000079424
650    _2
$a TNF-alfa $7 D014409
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Shaddick, Gavin $u G. Shaddick, PhD, Department of Mathematics, University of Exeter, Exeter, UK
700    1_
$a Charlton, Rachel $u R. Charlton, PhD, N. McHugh, MBChB, MD, FRCP, FRCPath, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
700    1_
$a Cavill, Charlotte $u C. Cavill, BSc, R. Holland, MD, Royal National Hospital for Rheumatic Diseases, Bath, UK
700    1_
$a Holland, Richard $u C. Cavill, BSc, R. Holland, MD, Royal National Hospital for Rheumatic Diseases, Bath, UK
700    1_
$a Iannone, Florenzo $u F. Iannone, MD, PhD, G. Lapadula, MD, S. Lopriore, MD, Rheumatology Unit-DETO, University of Bari, Bari, Italy
700    1_
$a Lapadula, Giovanni $u F. Iannone, MD, PhD, G. Lapadula, MD, S. Lopriore, MD, Rheumatology Unit-DETO, University of Bari, Bari, Italy
700    1_
$a Lopriore, Simona $u F. Iannone, MD, PhD, G. Lapadula, MD, S. Lopriore, MD, Rheumatology Unit-DETO, University of Bari, Bari, Italy
700    1_
$a Závada, Jakub $u J. Závada, MD, PhD, K. Pavelka, MD, PhD, Institute of Rheumatology, Prague, Czech Republic
700    1_
$a Uher, Michal $u M. Uher, MSc, L. Szczuková, MD, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0237556
700    1_
$a Pavelka, Karel $u J. Závada, MD, PhD, K. Pavelka, MD, PhD, Institute of Rheumatology, Prague, Czech Republic
700    1_
$a Szczuková, Lenka $u M. Uher, MSc, L. Szczuková, MD, Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Sidiropoulos, Prodromos $u P. Sidiropoulos, MD, PhD, I. Flouri, MD, Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece
700    1_
$a Flouri, Irini $u P. Sidiropoulos, MD, PhD, I. Flouri, MD, Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece
700    1_
$a Drosos, Alexandros $u A. Drosos, MD, PhD, Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
700    1_
$a Möller, Burkhard $u B. Möller, Professor, Department of Rheumatology, Immunology & Allergology, Inselspital, University Hospital Bern, Bern, Switzerland
700    1_
$a Nissen, Michael J $u M.J. Nissen, MBBS, FRACP, Department of Rheumatology, University Hospital Geneva, Geneva, Switzerland
700    1_
$a Müller, Rüdiger B $u R.B. Müller, MD, Cantonal Hospital, Lucerne, Switzerland
700    1_
$a Scherer, Almut $u A. Scherer, PhD, SCQM Foundation, Zürich, Switzerland. N. McHugh and A. Nightingale are joint senior authors
700    1_
$a McHugh, Neil $u R. Charlton, PhD, N. McHugh, MBChB, MD, FRCP, FRCPath, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK; n.j.mchugh@bath.ac.uk
700    1_
$a Nightingale, Alison $u A. Nightingale, PhD, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
773    0_
$w MED00002935 $t The Journal of rheumatology $x 0315-162X $g Roč. 48, č. 1 (2021), s. 48-57
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32238520 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20220117123749 $b ABA008
999    __
$a ok $b bmc $g 1715096 $s 1146780
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 48 $c 1 $d 48-57 $e 20200401 $i 0315-162X $m Journal of rheumatology $n J Rheumatol $x MED00002935
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options